CN114409735A - Clinacanthus nutans antioxidant undecapeptide and preparation method and application thereof - Google Patents
Clinacanthus nutans antioxidant undecapeptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN114409735A CN114409735A CN202210103859.XA CN202210103859A CN114409735A CN 114409735 A CN114409735 A CN 114409735A CN 202210103859 A CN202210103859 A CN 202210103859A CN 114409735 A CN114409735 A CN 114409735A
- Authority
- CN
- China
- Prior art keywords
- antioxidant
- undecapeptide
- clinacanthus nutans
- clinacanthus
- nutans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 48
- 241000123852 Clinacanthus nutans Species 0.000 title claims abstract description 47
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000004007 reversed phase HPLC Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 3
- 238000002835 absorbance Methods 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 241001579122 Clinacanthus Species 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 3
- 238000003916 acid precipitation Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000001644 anti-hepatocarcinoma Effects 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 101800000068 Antioxidant peptide Proteins 0.000 abstract description 13
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 10
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 abstract description 8
- 238000000746 purification Methods 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 235000019462 natural additive Nutrition 0.000 abstract 1
- 238000012827 research and development Methods 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 25
- 239000000243 solution Substances 0.000 description 16
- -1 oxygen radicals Chemical class 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 230000007760 free radical scavenging Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000270722 Crocodylidae Species 0.000 description 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- SAKCBXNPWDRWPE-BQBZGAKWSA-N Asp-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)N SAKCBXNPWDRWPE-BQBZGAKWSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 101150116862 KEAP1 gene Proteins 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- QKQDTEYDEIJPNK-GUBZILKMSA-N Ser-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO QKQDTEYDEIJPNK-GUBZILKMSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The patent discloses an antioxidant undecapeptide of clinacanthus nutans and a preparation method and application thereof, wherein the antioxidant undecapeptide is DMGPPLSEKLH. The clinacanthus nutans antioxidant peptide is prepared by taking clinacanthus nutans as a raw material and adopting an ultrasonic-assisted alkali-soluble acid extraction technology, and a purification method of the clinacanthus nutans antioxidant peptide is further established by separation and purification technologies such as ion chromatography, reversed-phase high performance liquid chromatography and the like. In vitro antioxidant experiments show that the clinacanthus nutans antioxidant undecapeptide can effectively remove free radicals such as DPPH, ABTS, hydroxyl free radicals and the like, has the characteristics of simple structure, strong antioxidant activity and high safety, can be used as a good substitute of a chemically synthesized antioxidant, has certain antitumor activity, and provides theoretical basis and practical reference for research and development of novel natural additives in the industries of foods, medicines and cosmetics.
Description
Technical Field
The invention relates to clinacanthus nutans antioxidant peptide and a preparation method and application thereof, and belongs to the technical field of food and medicine.
Background
Clinacanthus nutans, also known as crocodile flower, is a plant of the genus crocodile of the family Acanthaceae. Clinacanthus nutans is widely distributed from tropical zone of south China to Malaysia, Java, Calimanda and other places in south China, Hainan, Guangdong, Guangxi and Yunnan. Clinacanthus nutans mostly grows in low-altitude sparse forest close to equator or in moist sandy soil in a bush, is a high and large herbaceous plant, is in an upright or climbing shape, and is in a light green shape when stems are cylindrical and dry. Clinacanthus nutans is generally taken as a medicine by whole plants or leaves, is sweet in taste, slightly bitter and cool in nature, and has the effects of clearing heat and promoting diuresis, inducing diuresis and reducing edema, activating blood and dredging channels, removing dampness, resisting tumors and the like.
Free radicals are atoms or radicals having unpaired electrons, which are intermediates of human metabolism. The proliferation of free radicals in the body can induce oxidative stress, and the antioxidant defense system of the body is seriously unbalanced, thereby causing cell damage. Under normal conditions, the body produces reactive oxygen radicals: (Reactive oxygen speciesROS) can be maintained at a low level under the action of own antioxidant enzyme systems (superoxide dismutase, catalase, glutathione peroxidase and the like) and endogenous antioxidants (VE, VC, carnosine, glutathione and the like), so that the body is not damaged by free radicals, and meanwhile, when endogenous or exogenous stimulation promotes abnormal metabolism of the body to generate a large amount of ROS or the balance between the antioxidant and the oxidant of the body is abnormal along with the growth of the age, oxidative stress can be caused, namely, the excessive ROS can damage the normal redox level of the bodyBalance, causing oxidative damage to biological macromolecules (such as protein, lipid, DNA and the like) in cells, thereby accelerating the aging of the organism and causing various diseases such as neurodegenerative diseases, atherosclerosis, chronic inflammation, cancer and the like.
The antioxidant can effectively inhibit negative effects caused by oxidative stress in human body, and can protect tissues and organs from being damaged by ROS. Synthetic antioxidants such as BHT, PG, etc. have a good function of scavenging free radicals, but have a certain toxic effect on the enzyme system of the human body, while natural antioxidants have both strong antioxidant activity and high safety, so people gradually turn their research into natural antioxidants. The antioxidant peptide is one of the main members of natural antioxidants, participates in the processes of antioxidation and detoxification in organism cells, and the reduction of the antioxidant capacity can induce the cells to generate oxidative stress, cause the damage and the function loss of the cells, and have close relation with the occurrence of cell aging and diseases. The antioxidant active polypeptide has the characteristics of low toxicity, high efficiency and the like, and is considered as an ideal substitute of artificially synthesized antioxidants as an antioxidant for food and organisms. The antioxidant active polypeptide can effectively remove excessive ROS (such as hydroxyl free radical, superoxide anion free radical, nitric oxide free radical, etc.) in vivo, protect normal structure and function of cells and mitochondria, prevent lipid peroxidation, and help organism resist diseases. Research has demonstrated that ROS play an important role in the development of cancer. They are required for normal physiological activities such as intracellular signaling and homeostasis, cell death, etc. at appropriate concentrations. Excessive ROS easily attack deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), cause cell mutation, inhibit the expression of cancer suppressor genes and induce cell canceration. Under oxidative stress, free radicals are continuously and excessively generated, and then DNA, protein and lipid are damaged, and the health of cells is threatened, so that diseases are caused. A large number of researches show that Keap1-Nrf2/ARE is an important oxidative stress path of a body, wherein Nrf2 is a key factor, and the key factor can prevent normal cell degeneration and promote tumor development. When the organism in the physiological state is in an oxidative stress state, Keap1 and Nrf2Uncoupling, nuclear incorporation after phosphorylation of Nrf2 and anti-oxidant reaction element(s) ((Antioxidant ResponseElementAnd ARE) to start the downstream II phase detoxification enzyme regulated and controlled by ARE, and improve the anti-oxidative stress capability of cells, thereby playing a role in preventing tumors. The cationic peptide has the characteristics of easy modification and easy combination with tumor cells, and has lower toxicity to normal cells, so that the cationic peptide has better anti-tumor potential.
At present, the chemical components and pharmacological activity of clinacanthus nutans are rarely researched at home and abroad, and particularly, the protein and polypeptide of clinacanthus nutans are rarely researched. Therefore, it is necessary to study the preparation of polypeptide and antioxidant activity of Clinacanthus nutans by Clinacanthus nutans research subjects, and important scientific basis is provided for the comprehensive development of Clinacanthus nutans and the application of Clinacanthus nutans in the fields of foods, medicines and the like.
Disclosure of Invention
The invention aims to provide clinacanthus nutans antioxidant undecapeptide and a preparation method and application thereof.
The comparison of a Uniprot database and a NCBI database shows that the amino acid sequence of the antioxidative undecapeptide is Asp-Met-Gly-Pro-Pro-Leu-Ser-Glu-Lys-Leu-His, and is represented by DMGPPLSEKLH with a single letter.
The method comprises the following steps of extracting clinacanthus nutans crude protein by an ultrasonic-assisted alkali-soluble acid precipitation method, and then carrying out anion exchange chromatography, reverse high performance liquid chromatography separation and purification, identification and synthesis to obtain the clinacanthus nutans antioxidant undecapeptide, and the specific steps comprise:
1) extracting the protein in clinacanthus nutans by adopting an alkali-soluble acid precipitation method to prepare a crude extract of the clinacanthus nutans protein;
2) separating the crude extract of clinacanthus nutans protein by using DEAE-Sepharose ion exchange chromatography, eluting with 0.2 mol/L to 1 mol/L NaCl Tris-hydrochloric acid buffer solution with pH =8.4 in a linear gradient manner at a flow rate of 1mL/min, detecting the absorbance of an effluent sample by using a chromatographic chart acquisition analyzer HD-A, collecting each peak component, measuring the antioxidant activity, and collecting the component CNPH-III with the highest activity;
3) and (3) further separating and purifying CNPH-III by using reverse phase high performance liquid chromatography (RP-HPLC), wherein the mobile phase A is acetonitrile containing 0.1% TFA, the mobile phase B is deionized water containing 0.1% TFA, and the elution gradient of the RP-HPLC is as follows: 0-5min, 5% -10% A; 5-15min, 10% -50% A; 15-35 min, 50% -80% A, flow rate of mobile phase of 1.0 mL/min, detection wavelength of 214 nm, and collecting the component with highest activity (retention time of elution peak of 3-4 min);
4) adopting liquid chromatography mass spectrometer to carry out amino acid sequence determination to the peptide section that the elution peak that retention time is 3-4min contained, carrying out Fmoc solid phase synthesis to the amino acid sequence that obtains of survey, thereby obtain the antioxidative undecapeptide of clinacanthus nutans.
The clinacanthus nutans antioxidant undecapeptide provided by the invention can be applied to preparation of anti-liver cancer drugs.
The clinacanthus nutans antioxidant undecapeptide provided by the invention can also be applied to preparation of products with antioxidant functions.
The invention has the following remarkable advantages:
the clinacanthus hypochondriacus antioxidant undecapeptide DMGPPLSEKLH provided by the invention has strong DPPH, OH and ABTS free radical scavenging capacity, and shows that the clinacanthus hypochondriacus antioxidant undecapeptide has important value in the aspects of development and application of antioxidant activity. When the concentration of the peptide reaches 2 mg/mL, the DPPH, ABTS and hydroxyl free radical clearance rates are 37.858 +/-1.001%, 16.569 +/-0.554% and 65.983 +/-1.191%, respectively. IC of antioxidant peptide DMGPPLSEKLH for DPPH free radical clearance rate50IC of value 19.064 + -1.569 mg/mL for ABTS free radical clearance50IC of value 19.771 + -5.003 mg/mL, for hydroxyl radical clearance50The value was 1.013. + -. 0.050 mg/mL. When the concentration of the antioxidant peptide DMGPPLSEKLH is 10 mg/mL, the inhibition rate of HepG2 cells reaches 56.213 +/-1.739%. The antioxidant undecapeptide has a certain anti-liver cancer effect.
Drawings
FIG. 1 is a chromatogram of DEAE sepharose anion of a crude extract of clinacanthus nutans.
FIG. 2 is a reverse phase high performance liquid chromatogram of anion chromatography elution peak III.
Fig. 3 is a mass spectrum of antioxidant peptide DMGPPLSEKLH.
Fig. 4 shows the effect of natural antioxidant peptide DMGPPLSEKLH on free radical scavenging. A: ABTS free radical scavenging activity; b: DPPH free radical scavenging activity; c: hydroxyl radical scavenging activity.
FIG. 5 shows the inhibitory effect of natural antioxidant peptide DMGPPLSEKLH on HepG-2 cells.
Detailed Description
The present embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation manner and process are given, but the scope of the present invention is not limited to the following implementation examples.
Example 1 separation and purification of crude extract of Clinacanthus nutans
Clinacanthus nutans pretreatment: the surface of clinacanthus nutans is cleaned, blackened and rotten clinacanthus nutans leaves are removed, and then the clinacanthus nutans are ground by liquid nitrogen for standby.
Extracting clinacanthus nutans crude protein and polypeptide: the ground clinacanthus nutans powder is prepared by mixing the following raw materials in a liquid-to-solid ratio of 1: 10 (m/v) distilled water was added, the ultrasonic power was set at 135W, and ultrasonic was performed at 25 ℃ for 35 min. Then filtering out residues, adjusting the pH value of the filtrate to 8.0 by using 1 mol/L NaOH, stirring the filtrate at room temperature for 30 min, centrifuging the filtrate at 5000 r/min for 20 min, adjusting the pH value of the centrifuged supernatant to 3 by using 1 mol/L HCl, centrifuging the supernatant at 5000 r/min for 20 min, dissolving the centrifuged precipitate in 10-30 mL of Tris-hydrochloric acid buffer solution with the pH value of 8.4, then filling the solution into a dialysis bag with the molecular weight cutoff of 3500D, dialyzing the solution in deionized water overnight, and freeze-drying to obtain the crude Clinacanthus nutans protein.
And (3) anion chromatography separation and purification: preparing the clinacanthus nutans crude protein lyophilized powder into 6 mg/ml solution with 0.02M Tris-hydrochloric acid buffer solution with pH of 8.4, completely dissolving, filtering with 0.22 μ M pore diameter microfiltration membrane, then separating and purifying by DEAE-Sepharose ion exchange column chromatography, balancing with 0.02M Tris-hydrochloric acid buffer solution with pH value of 8.4, loading the filtered sample on the column with flow rate of 1mL/min, eluting with 0.2 mol/L to 1 mol/L NaCl Tris-hydrochloric acid buffer solution with pH =8.4 in linear gradient, detecting the absorbance of the effluent sample by a chromatogram collection analyzer HD-A, collecting 3 peak components according to elution peak (figure 1), comparing hydroxyl free radical, DPPH, ABTS free radical scavenging ability, collecting highest active component (CNPH-III), vacuum freeze drying, and storing at-20 deg.C.
Separating and purifying by reversed-phase high performance liquid chromatography: dissolving the CNPH-III freeze-dried powder with deionized water, filtering with a 0.22 mu m pore diameter microfiltration membrane, and separating and purifying by using a Thermo C18 chromatographic column, wherein the sample concentration is 10 mg/mL, the sample injection amount is 20 mu L, and the mobile phase A: acetonitrile with mass fraction of 0.1% TFA, mobile phase B: deionized water containing 0.1% TFA by mass fraction, and the flow rate of the mobile phase was 1.0 mL/min. Adopting a gradient elution mode, wherein the elution conditions are as follows: 0-5min, 5% -10% of mobile phase A; 5-15min, 10% -50% of mobile phase A; 15-35 min, 50% -80% mobile phase A. The detection wavelength was 214 nm. Measuring scavenging ability of hydroxyl free radical, DPPH, and ABTS free radical of the eluate corresponding to each absorption peak, collecting eluate (CNPH-III-2 with highest antioxidant activity, FIG. 2) with retention time of 3-4min, and vacuum freeze drying.
Freeze-drying the collected antioxidant components, determining the amino acid sequence by a liquid chromatography-mass spectrometry (LC-MS/MS) method (figure 3), and finding a new peptide by comparing a Uniprot database with an NCBI database to obtain the amino acid sequence of the antioxidant peptide: DMGPPLSEKLH are provided. The amino acid sequence was sent to Gill Biochemical Co., Ltd, Shanghai for Fmoc solid phase synthesis.
Example 2 in vitro antioxidant Activity assay of Natural antioxidant peptides
Weighing the synthetic polypeptide freeze-dried sample, and preparing sample solutions with different concentrations.
DPPH radical clearance: 3.94mg of DPPH is accurately weighed, dissolved by ethanol with volume fraction of 95 percent, and prepared into 0.1 mmo1/L DPPH solution after the volume is adjusted to 100 mL. Mixing 1mL sample solution and 1mL DPPH solution, standing at room temperature in dark place for 30 min, and measuring light absorption value at 517 nm; 1mL of ethanol solution with 95% volume fraction is used as a control group instead of DPPH solution; a blank was prepared by replacing the sample with 1mL of distilled water. The DPPH radical clearance of the samples was calculated using the following formula:
in the formula: a. the1-absorbance of the sample set; a. the2-control absorbance values; a. the3Blank control groupAbsorbance value
ABTS free radical scavenging activity: a 7 mM stock solution of ABTS and a 2.45 mM solution of potassium persulfate were prepared and mixed in a 1: 1, placing the mixture in a dark place for 16 hours at room temperature, and then diluting the mixture by using 5mM phosphate buffer solution with pH7.4 until the light absorption value at 734 nm is 0.70 +/-0.02 to obtain the ABTS free radical solution. 1mL of ABTS free radical solution and 1mL of sample solution with different concentrations are mixed in equal volume, reacted at room temperature for 10 min, and then the absorbance is measured at 734 nm. Distilled water was used as a blank instead of the sample. The ABTS free radical scavenging activity of the samples was calculated according to the following formula:
in the formula: a. the1-absorbance of the sample set; a. the2Blank set absorbance value
Hydroxyl radical scavenging activity: 8mmol/L ferrous sulfate solution, 3 mmol/L salicylic acid solution and 20mmol/L hydrogen peroxide solution are prepared for standby. And (3) fully mixing 200 mu L of sample solution with 60 mu L of 8mmol/L ferrous sulfate, 200 mu L of 20mmol/L salicylic acid and 50 mu L of 20mmol/L hydrogen peroxide, incubating in a water bath at 37 ℃ for 30 min, cooling to room temperature, adding 90 mu L deionized water, and centrifuging at 4000 rpm for 30 min. The supernatant was taken to measure the absorbance of the reaction at 510 nm. Distilled water was used as a blank control. The scavenging activity of hydroxyl radicals is calculated according to the following formula:
in the formula: a. the0-blank set absorbance values; a. the1Absorbance of sample set
As measured by the example, the clinacanthus nutans antioxidant peptide DMGPPLSEKLH has a better clearance rate for DPPH radical, ABTS radical and hydroxyl radical as shown in fig. 4.
EXAMPLE 3 HepG-2 cytotoxicity and anticancer Studies of Natural antioxidant undecapeptide
Cell culture: HepG-2 cells inDMEM medium with 10% FBS by volume at 37 ℃ in 5% CO2Culturing and subculturing in an incubator. Observing under an inverted microscope until the cells grow and fuse to 80%, draining the culture solution in a sterile operating platform, cleaning the cell surface layer by PBS phosphate buffer solution with pH of 7.3 (purchased from 23.48 g/2L of Hippo east China Biotech Co., Ltd.) and adding 1mL of pancreatin digestive juice, placing the cell surface layer in an incubator at 37 ℃ for 5 minutes, and then adding 1mL of DMEM culture medium containing 10% FBS by volume fraction to stop the action of the pancreatin digestive juice. All the liquid was then transferred into a 1.5 mL centrifuge tube and centrifuged at 2000 rpm for 10 min. After centrifugation, the supernatant was discarded, and fresh DMEM medium was added to the pellet, and the cells were uniformly dispersed by several times of pipetting. Cells were evenly distributed in fixed proportions into various sizes of petri dishes according to the experimental design.
Determination of cell growth viability: the CCK-8 method was used to determine the effect of clinacanthus hypochondriacus antioxidant undecapeptide DMGPPLSEKLH on the growth viability of cells HepG2, when the cells were fused to 80% -90%, the cells were washed with PBS buffer (23.48 g/2L from AoRuiyuan Biotech Co., Ltd., Mitsui) of pH 7.3 preheated at 37 ℃ in advance to remove surface residual serum, 1mL of pancreatic digestion solution was added, digestion was performed in a 37 ℃ incubator for 5min, after the cells were floated, 1mL of DMEM medium containing 10% FBS by volume was added to the dish to terminate the digestion, and then the cells HepG-2 were treated with 1X 10 FBS5cells/mL were seeded in 96-well plates at a density of 90. mu.L per well, with 4 replicate wells per concentration gradient in parallel. 37 ℃ and 5% CO2Culturing in an incubator for 24 h, adding 10 μ L of DMEM medium containing Clinacanthin antioxidant undecapeptide DMGPPLSEKLH to each well, wherein the concentration gradient of Clinacanthin antioxidant undecapeptide is 0, 2, 4, 6, 8, and 10 mg/mL, and culturing for 24 h. After the culture solution was aspirated, 100. mu.L of CCK-8 (prepared in DMEM medium) containing 10% by volume fraction was added, and after incubation for 1 hour in an incubator, the absorbance was measured at a wavelength of 450 nm using a microplate reader. The inhibition rate of each group of drugs on cells was calculated according to the following formula:
in the formula: a. the1-blank set absorbance values; a. the2-control absorbance values; a. the3Absorbance of sample set
The clinacanthus nutans antioxidant peptide DMGPPLSEKLH measured by the example has a high inhibition rate on HepG-2, which indicates that it has a good effect on resisting liver cancer (FIG. 5).
The above description is only a preferred embodiment of the present invention, and all equivalent changes and modifications made in the claims of the present invention should be covered in the protection scope of the present invention.
SEQUENCE LISTING
<110> Fuzhou university
<120> clinacanthus nutans antioxidant undecapeptide and preparation method and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 11
<212> PRT
<213> Artificial sequence
<400> 1
Asp Met Gly Pro Pro Leu Ser Glu Lys Leu His
1 5 10
Claims (4)
1. The clinacanthus nutans antioxidant undecapeptide is characterized in that: the amino acid sequence of the clinacanthus nutans antioxidant undecapeptide is Asp-Met-Gly-Pro-Pro-Leu-Ser-Glu-Lys-Leu-His.
2. A method for preparing the clinacanthus nutans antioxidant undecapeptide as claimed in claim 1, wherein the method comprises the following steps: the method comprises the following steps:
1) precipitating and extracting proteins in clinacanthus nutans by adopting an alkali-soluble acid precipitation method to prepare a crude extract of the clinacanthus nutans proteins;
2) separating the crude extract of clinacanthus nutans protein by using DEAE-Sepharose ion exchange chromatography, eluting with 0.2-1 mol/L NaCl Tris-hydrochloric acid buffer solution with pH =8.4 in linear gradient at the flow rate of 1mL/min, detecting the absorbance of an effluent sample by using a chromatographic chart acquisition analyzer HD-A, collecting each peak component, measuring the antioxidant activity, and collecting the component CNPH-III with the highest antioxidant activity;
3) and (3) further separating and purifying CNPH-III by using reverse phase high performance liquid chromatography (RP-HPLC), wherein the mobile phase A is acetonitrile containing 0.1% TFA, the mobile phase B is deionized water containing 0.1% TFA, and the elution gradient of the RP-HPLC is as follows: 0-5min, 5% -10% A; 5-15min, 10% -50% A; 15-35 min, 50% -80% A, the flow rate of mobile phase is 1.0 mL/min, the detection wavelength is 214 nm, and the elution peak with retention time of 3-4min is collected;
4) adopting liquid chromatography mass spectrometer to carry out amino acid sequence determination to the peptide section that the elution peak that retention time is 3-4min contained, carrying out Fmoc solid phase synthesis to the amino acid sequence that obtains of survey, thereby obtain the antioxidative undecapeptide of clinacanthus nutans.
3. The use of the clinacanthus hypochondriacus antioxidant undecapeptide as claimed in claim 1 in the preparation of an anti-hepatoma drug.
4. The use of the clinacanthus hypochondriacus antioxidant undecapeptide as claimed in claim 1 in preparing a product with an antioxidant function.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210103859.XA CN114409735B (en) | 2022-01-28 | 2022-01-28 | Clinopodium polycephalum antioxidation undecapeptide and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210103859.XA CN114409735B (en) | 2022-01-28 | 2022-01-28 | Clinopodium polycephalum antioxidation undecapeptide and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114409735A true CN114409735A (en) | 2022-04-29 |
CN114409735B CN114409735B (en) | 2023-11-21 |
Family
ID=81279839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210103859.XA Active CN114409735B (en) | 2022-01-28 | 2022-01-28 | Clinopodium polycephalum antioxidation undecapeptide and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114409735B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102964427A (en) * | 2012-12-12 | 2013-03-13 | 上海交通大学 | Bioactive polypeptide QEPVL, and preparation and application thereof |
CN105341570A (en) * | 2015-10-14 | 2016-02-24 | 哈尔滨工业大学 | Series Clinacanthus nutans functional beverage and preparation method thereof |
CN106317170A (en) * | 2016-10-13 | 2017-01-11 | 福州大学 | Antioxidant peptide in perilla seeds and application thereof |
CN108794577A (en) * | 2018-06-26 | 2018-11-13 | 福州大学 | A kind of preparation method of antioxidation polypeptide |
CN112121144A (en) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
-
2022
- 2022-01-28 CN CN202210103859.XA patent/CN114409735B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102964427A (en) * | 2012-12-12 | 2013-03-13 | 上海交通大学 | Bioactive polypeptide QEPVL, and preparation and application thereof |
CN105341570A (en) * | 2015-10-14 | 2016-02-24 | 哈尔滨工业大学 | Series Clinacanthus nutans functional beverage and preparation method thereof |
CN106317170A (en) * | 2016-10-13 | 2017-01-11 | 福州大学 | Antioxidant peptide in perilla seeds and application thereof |
CN108794577A (en) * | 2018-06-26 | 2018-11-13 | 福州大学 | A kind of preparation method of antioxidation polypeptide |
CN112121144A (en) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
Non-Patent Citations (3)
Title |
---|
AMALINA AHMAD AZAM 等: "Multi-platform metabolomics analyses revealed the complexity of serum metabolites in LPS-induced neuroinfl ammed rats treated with clinacanthus nutans aqueous extract", FRONTIERS IN PHARMACOLOGY, vol. 12, pages 1 - 15 * |
DANMIN HUANG 等: "Purification and characterization of a novel polysaccharide–peptide complex from Clinacanthus nutans Lindau leaves", CARBOHYDRATE POLYMERS, vol. 137, pages 701 - 708 * |
廖芳 等: "大孔吸附树脂纯化美洲大蠊多肽的工艺研究", 中草药, vol. 47, no. 19, pages 3420 - 3425 * |
Also Published As
Publication number | Publication date |
---|---|
CN114409735B (en) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110655556B (en) | Preparation and method of immunoregulatory peptide | |
CN113248568B (en) | Selenium-rich cordyceps militaris active selenium peptide with neuron protection function and preparation method and application thereof | |
CN116514912B (en) | Straw mushroom polypeptide for resisting skin oxidative damage and application thereof | |
CN114230635A (en) | High-activity selenium-rich oyster antioxidant peptide and application thereof | |
CN114989248B (en) | Clinopodium polycephalum polypeptide with anti-inflammatory and antioxidant activities, and preparation method and application thereof | |
CN109503699B (en) | Antihypertensive peptide containing hairtail flesh | |
CN110590912A (en) | Novel antioxidant active polypeptide OA-VI12 as well as preparation method and application thereof | |
CN116621934B (en) | Polypeptide derived from straw mushrooms and used for resisting skin oxidation and inhibiting oxidative stress and application thereof | |
CN114588184B (en) | Herba Saururi extract, and preparation method and application thereof | |
CN111732634B (en) | Application of earthworm active peptide for inhibiting melanocyte proliferation in preparation of medicines or cosmetics | |
CN114409735B (en) | Clinopodium polycephalum antioxidation undecapeptide and preparation method and application thereof | |
CN105601707B (en) | A kind of anti-oxidant tetrapeptide of dandelion seed and preparation method thereof | |
CN115724907B (en) | Dictyophora rubrovalvata polypeptide and application thereof | |
CN112245342A (en) | Ginseng series skin care extract and preparation method and application thereof | |
CN109748951B (en) | Angelica sinensis antioxidant polypeptide and preparation method and application thereof | |
CN114573664B (en) | Anti-oxidation tridecape of clindamianum as well as preparation method and application thereof | |
CN108191958B (en) | Linseed meal antioxidant hexapeptide and preparation method and application thereof | |
CN114163494B (en) | Preparation method and application of octopus antioxidant peptide for antagonizing oxidative stress injury | |
CN110812469A (en) | Application of polypeptide AR12 in preparation of antioxidant | |
CN112521446B (en) | ACE inhibitory peptide and application thereof | |
He et al. | Components and Antioxidant Activity of the Polysaccharide from Streptomyces virginia H03 | |
CN111978370A (en) | Chia seed antioxidant peptide and preparation method and application thereof | |
CN113201046A (en) | Walnut meal anti-inflammatory peptide FPY and application thereof | |
CN106309613B (en) | Chinese medicine with anti-inflammatory and anti-allergic effects and preparation method thereof | |
CN116284244B (en) | Dictyophora rubrovalvata polypeptide applied to preparation of antioxidant drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |